By: Tan Liwu, Zhang Hongyu, Li Jinzen*
Abstract: Objective: To analyze the mechanism of Shexiang Baoxin Pills (SBP) against coronary artery lesions (CAL) via network pharmacology and validate it clinically. Methods: SBP components and targets were screened via TCMSP, TCMID, and Swiss Target Prediction. Intersecting with CAL targets from GeneGards formed a "drug‑ingredient‑target‑disease" network. STRING and DAVID supported PPI topology, GO annotation, and KEGG enrichment. A "pathway‑target‑ingredient"
Keywords: Shexiang Baoxin Pill; Coronary artery lesions; Network pharmacology; Mechanism of action
International Journal of Pharmacy and Pharmacology 2026, 17(1), 1-6;
https://doi.org/10.58244/ijpp.263553